ASIT biotech is a clinical stage (Phase 3) biopharmaceutical company publicly listed on EURONEXT (Brussels & Paris).
ASIT biotech’s mission is to lead an evolution in allergy therapeutics by creating a new generation of highly effective and efficient immunotherapy options for respiratory and food allergies. Our goal is to generate breakthrough treatments that deliver rapid, recognizable improvement in the life of allergy patients, within weeks rather than months or years following treatment initiation.
- ASIT biotech announces the publication of its 2020 annual report Friday, 30 April 2021
- Signature of the binding contribution agreement relating to the contribution of the medical imaging division of DMS Group to ASIT biotech Friday, 16 April 2021
- Resumption of negotiations between ASIT biotech and DMS Thursday, 08 April 2021 All ASIT news